Please select the option that best describes you:
Would you provide the KEYNOTE-522 regimen for a patient with ER low, PR+, HER2- stage IIIb breast cancer?
ER low being 1-9% (<10%), PR 20%
Answer from: Medical Oncologist at Academic Institution
I think it is reasonable to use the KEYNOTE-522 regimen for a patient with stage IIIB breast can with a tumor that is ER-low (<10%), PR+ and HER2-negative, but with many caveats. Both biological and clinical outcomes data suggest that such cases are closer to HR-negative (as is ER-/PR+ disease). ...
Sign in or Register to read more